全部照片(1)
About This Item
經驗公式（希爾表示法）:
C8H8N4 · HCl
CAS號碼:
分子量：:
196.64
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推薦產品
等級
pharmaceutical primary standard
API 家族
hydralazine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
Cl[H].N\N=C1/N=NC=C2C=CC=CC12
InChI
1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5,7H,9H2;1H/b11-8-;
InChI 密鑰
SECXUXOCDLQOBI-MKFZHGHUSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Hydralazine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
抑制DNA甲基转移酶并调节基因表达的表观遗传调控。非选择性MAO-A/B抑制剂；降压药；氨基脲敏感性胺氧化酶抑制剂。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
Hydralazine and hydralazine hydrochloride.
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, 24, 85-100 (1980-01-01)
Sofie Gevaert et al.
Acta cardiologica, 69(2), 193-196 (2014-05-03)
Heart failure is an established predictor of primary cardiac events during pregnancy. Adequate heart failure treatment in pregnant women is hampered by important foetotoxicity of several conventional drugs. Hydralazine with or without long-acting nitrates has been proposed as an alternative
Fumiki Yoshihara et al.
Clinical and experimental nephrology, 19(2), 197-207 (2014-05-23)
The infusion of chronic angiotensin II (Ang II) has been shown to promote renal interstitial fibrosis. To evaluate the pathophysiological significance of the natriuretic peptide-GC-A system, we infused Ang II (1.0 mg/kg/day) in GC-A-deficient mice (GC-A-KO). We used 5 groups
Keith C Ferdinand
Expert review of cardiovascular therapy, 3(6), 993-1001 (2005-11-19)
In the USA alone, there are over 5,000,000 people diagnosed with heart failure. A disproportionate number of African-Americans are affected by this disease, with increased morbidity and mortality, yet they are tremendously under-represented in clinical trials. Several drugs have been
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Gustavo H Oliveira-Paula
The American journal of cardiology, 114(7), 1126-1126 (2014-09-13)
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務